Q2 2025 Management View Jonathan Eitan Solomon, CEO, reported that "the second quarter of 2025 has been a productive period for BiomX as we continue to advance our clinical programs and build ...

Thank you, and welcome to the BiomX conference call to review the company's second quarter 2025 financial results and provide an update on our business and programs. Later today, we will file the ...

Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communication ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

PANTHERx® Rare Pharmacy, a leader in rare disease product patient access and support services in the United States, announced ...

Lung clearance index, lung function and respiratory symptoms improved in children aged 6 to 11 years with cystic fibrosis ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

Vertex Pharmaceuticals’ second quarter 2025 results exceeded Wall Street’s expectations, but the market responded sharply ...

Armata achieved a major milestone with positive topline results from its Phase 1b/2a clinical trial of AP-SA02 for Staphylococcus aureus bacteremia. These 10 stocks could mint the next wave of ...

AAP FACTCHECK - A severely emaciated Palestinian child who appeared on the front page of newspapers around the world as a ...

Insmed shares got a wave of bullish calls Tuesday after U.S. regulators cleared its new drug Brinsupri, the first treatment ...